SciSparc Ltd. (SPRC)
NASDAQ: SPRC · Real-Time Price · USD
3.900
-0.180 (-4.41%)
Oct 13, 2026, 1:59 PM EDT - Market open
SciSparc Employees
SciSparc had 3 employees as of December 31, 2025. The number of employees increased by 1 or 50.00% compared to the previous year. That makes SciSparc the 42,906th largest employer in the world and 7,002nd in the United States.
Employees
3
Change (1Y)
1
Growth (1Y)
50.00%
Revenue / Employee
$226,333
Profits / Employee
-$2,740,667
Market Cap
2.27M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 3 | 1 | 50.00% |
| Dec 31, 2024 | 2 | -1 | -33.33% |
| Dec 31, 2023 | 3 | 0 | - |
| Dec 31, 2022 | 3 | 0 | - |
| Dec 31, 2021 | 3 | 1 | 50.00% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Jaguar Health | 47 |
| PMGC Holdings | 34 |
| GeoVax Labs | 19 |
| BioRestorative Therapies | 14 |
| Genprex | 13 |
| Kairos Pharma | 4 |
| Oragenics | 3 |
| Silo Pharma | 3 |
SPRC News
- 6 days ago - SciSparc: Subsidiary NeuroThera Labs' CliniQuantum Reports Successful Quantum-Enabled Analysis of Billions of Gene Combinations Using Real-World Clinical Data on an S&P 500 Company's Quantum Architecture - GlobeNewsWire
- 20 days ago - SciSparc expands U.S. IP portfolio in collaboration with Clearmind Medicine - TheFly
- 20 days ago - SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations - GlobeNewsWire
- 5 weeks ago - SciSparc Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation for Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies - TheNewswire
- 5 weeks ago - SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation for Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies - TheNewswire
- 6 weeks ago - SciSparc subsidiary provides update on SCI-210 trial enrollment - TheFly
- 6 weeks ago - SciSparc: Subsidiary NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial - GlobeNewsWire
- 6 weeks ago - NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial - TheNewswire